Skip to main content
Home
FULL MENU Close Menu
Home
Home

HT Staff

News

FDA grants rezafungin QIDP and fast track designations

Author:
HT Staff
Publish date: September 28, 2018

The U.S.

  • Read More

News

Factors that may drive relapse in AYAs with ALL

Author:
HT Staff
Publish date: September 27, 2018

New research suggests race, clinical trial participation, and treatment duration may influence the risk of relapse in adolescents and young adults...

  • Read More

News

Study supports immediate compression after DVT

Author:
HT Staff
Publish date: September 27, 2018

Immediate compression therapy provides a “clear benefit” for patients with deep vein thrombosis (DVT), according to the senior author of a study...

  • Read More

News

Placenta-derived product receives orphan designation for HSCT

Author:
HT Staff
Publish date: September 27, 2018

The U.S.

  • Read More

News

FDA lifts partial hold on tazemetostat trials

Author:
HT Staff
Publish date: September 26, 2018

The U.S.

  • Read More

News

Blinatumomab approved to treat ALL in Japan

Author:
HT Staff
Publish date: September 26, 2018

The Japanese Ministry of Health, Labour and Welfare has approved blinatumomab (Blincyto®) for the treatment of relapsed or refractory B-cell acute...

  • Read More

News

FDA approves duvelisib for CLL/SLL and FL

Author:
HT Staff
Publish date: September 25, 2018

The U.S.

  • Read More

News

FLT3 inhibitor approved for rel/ref AML in Japan

Author:
HT Staff
Publish date: September 25, 2018

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the FLT3 inhibitor gilteritinib (Xospata®) to treat patients with FLT3-...

  • Read More

News

Drug approved as part of frontline therapy for HL

Author:
HT Staff
Publish date: September 25, 2018

The Japanese Ministry of Health, Labour and Welfare has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vinblastine, and...

  • Read More

News

Product approved to treat hemophilia A in Japan

Author:
HT Staff
Publish date: September 25, 2018

The Japanese Ministry of Health, Labour and Welfare has approved Jivi® (also known as damoctocog alfa pegol or antihemophilic factor [recombinant...

  • Read More

News

CHMP reconsiders new indication for blinatumomab

Author:
HT Staff
Publish date: September 24, 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) said it will re-examine a recent opinion on blinatumomab (...

  • Read More

News

CHMP backs proposed biosimilars of pegfilgrastim

Author:
HT Staff
Publish date: September 24, 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for three proposed biosimilars of...

  • Read More

News

CHMP recommends factor VIII therapy for hemophilia A

Author:
HT Staff
Publish date: September 24, 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for damoctocog alfa pegol, a...

  • Read More

News

CHMP supports new indication for venetoclax

Author:
HT Staff
Publish date: September 23, 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) approve a...

  • Read More

News

CHMP recommends mogamulizumab for MF, SS

Author:
HT Staff
Publish date: September 22, 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for mogamulizumab (Poteligeo)....

  • Read More

Pages

  • « first
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • last »

Privacy Policy

Do Not Sell My Personal Information

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close